Bicara Therapeutics Inc. BCAX
- Market cap
- $1.3B
- P/E
- 0.0×
Follow BCAX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 16.01 | 7.80 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 28.09 | 19.71 |
High Price
|
|||
| — | — | — | — | — | — | — | 32 | 55 | 103 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | (52) | (68) | (138) |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (52) | (68) | (138) |
Net Income
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (89.61) | (4.05) | (2.52) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (78.66) | (4.45) | (1.95) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (1.01) | 0.00 | (0.01) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (79.67) | (4.45) | (1.96) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (256.45) | 29.27 | 7.34 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 1 | 17 | 55 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | (46) | (75) | (107) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (1) | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | (46) | (75) | (107) |
FCF
|
|||
| — | — | — | — | — | — | — | 216 | 485 | 393 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | (230) | (490) | (415) |
Net Debt
|
|||
| — | — | — | — | — | — | — | (149) | 492 | 401 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (18.28%) | (29.32%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | (2,379.53%) | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | (39.63%) | (30.88%) |
ROE
|
|||
Bicara Therapeutics Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ORIC Oric Pharmaceuticals, Inc. | $1.4B | 0.0× | Compare |
| IMTX Immatics N.V. | $1.3B | 0.0× | Compare |
| DMRA Galecto, Inc. | $1.3B | 0.0× | Compare |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LBRX LB Pharmaceuticals Inc | $1.2B | 0.0× | Compare |
| DRTS Alpha Tau Medical Ltd. | $1.4B | 0.0× | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | 0.0× | Compare |
| REPL Replimune Group, Inc. | $1.2B | 0.0× | Compare |
Bicara Therapeutics Inc. (BCAX) key facts
- Bicara Therapeutics Inc. (BCAX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, BCAX traded at $19.21, a market capitalization of $1.3 billion.
- Return on equity was −30.9% and debt-to-equity 0.00.
Bicara Therapeutics Inc. (BCAX) Latest News
19 Aug
Bicara (BCAX) reports breakthrough 3-year Ficera data yet faces commercialization hurdles and execution risks from ongoing C-suite overhaul. Breakthrough data paired with leadership overhaul signals major strategic shifts likely to alter company trajectory and investor sentiment.
18 Aug
Bicara Therapeutics (BCAX) released its Q2 2026 earnings call transcript. Quarterly earnings calls deliver financial results that can shift near-term market views without guaranteeing major strategic shifts.
13 Aug
Bicara Therapeutics Inc. undergoes leadership shake-up with potential Ficerafusp Alfa milestone timeline adjustments that could alter the investment case. Leadership transitions combined with clinical milestone timeline shifts for a lead asset substantially influence biotech strategy execution and investor sentiment.
11 Aug
Bicara Therapeutics reported second quarter 2026 progress and announced strategic leadership transitions marking next era of execution and growth. Quarterly progress update combined with leadership transitions signals major strategic moves that could significantly alter company trajectory and investor sentiment.
Wedbush states Bicara Therapeutics cancer study remains on track for 2026 enrollment. Trial timeline confirmation offers moderate reassurance on pipeline without near-term catalysts.
Bicara Therapeutics Inc. (BCAX) held its Q2 2026 earnings call covering financial results and business updates. Q2 2026 earnings call delivers financial metrics and outlook that moderately influence BCAX performance and sentiment.
Bicara Therapeutics Inc. held its Q2 earnings call, covering financial results, pipeline progress, and operational updates for the period. Q2 earnings and call details typically deliver moderate insights into financials and strategy without major trajectory shifts.
1 Jun
Bicara Therapeutics Inc. (BCAX) issued its Q4 2025 earnings transcript covering financial results, operational updates, and forward outlook. Quarterly earnings data and outlook comments typically influence near-term sentiment and valuation without guaranteeing structural change.
22 May
Bicara Therapeutics reported positive ASCO data that strengthens support for Ficerafusp Alfa in head and neck cancer treatment. Positive ASCO data on lead asset improves clinical outlook and market positioning for Bicara.
21 May
Ficerafusp alfa plus pembrolizumab achieves differentiated three-year overall survival and deep responses driven by TGF-β inhibition in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. Positive survival data in lead oncology program strengthens Bicara's path to approval and commercial positioning.
15 May
Bicara Therapeutics Inc. stock surged 50%. One biotech investor allocated 29% of their portfolio to BCAX. Stock surge and large portfolio bet signal strong investor confidence that can shift market sentiment and trajectory.
14 May
Bicara Therapeutics reports encouraging progress on its cancer drug, generating optimism ahead of pivotal trial data expected in 2026. Drug development progress ahead of pivotal 2026 data represents a major pipeline milestone likely to enhance investor sentiment and stock trajectory.
12 May
Bicara Therapeutics Inc. (BCAX) highlighted strategic advances in its Q1 2026 earnings call, covering key operational progress and future outlook. Strategic advances in Q1 2026 earnings call signal major shifts enhancing BCAX's competitive position and investor sentiment.
11 May
Bicara Therapeutics Inc. (BCAX) Q1 2026 earnings call summary covers financial results, operational updates, and forward guidance for the biotech firm. Q1 2026 earnings call summary delivers major financial performance data and strategic insights likely to shift investor sentiment and BCAX trajectory.
Bicara Therapeutics Inc. (BCAX) released Q1 earnings call highlights, covering financial results, clinical pipeline updates, and strategic outlook for the biotech firm focused on cancer therapies. Q1 earnings call highlights detail financial performance, pipeline advancements, and future guidance, significantly influencing investor sentiment and stock trajectory.
Bicara Therapeutics Inc. (BCAX) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates influence financial performance assessment and short-term market sentiment.
1 Apr
Wall Street analysts predict Bicara Therapeutics Inc. (BCAX) could rally 54.85% and outline trading strategies. Analyst forecasts of 54.85% upside potential for BCAX could moderately boost investor sentiment and short-term stock performance.
Wall Street analysts forecast a 54.85% rally for Bicara Therapeutics Inc. (BCAX) stock and outline trading strategies to capitalize on the upside. Analyst predictions of 54.85% upside target moderately influence investor sentiment and near-term market performance.
31 Mar
Bicara Therapeutics Inc. (BCAX) Q4 2025 earnings call summary covers financial results, clinical pipeline updates, and strategic outlook for the biotech firm. Q4 2025 earnings summary details financials and pipeline progress, likely driving major shifts in BCAX valuation and investor confidence.
30 Mar
Bicara Therapeutics Inc. (BCAX) reported strong cash position in Q4 2025 earnings call highlights, alongside key operational updates. Strong cash position bolsters financial runway for clinical development, significantly impacting future performance and investor sentiment.
Bicara Therapeutics Inc. (BCAX) released highlights from its Q4 earnings call, covering financial results, pipeline updates, and strategic outlook. Q4 earnings call highlights detail financial performance and clinical progress that could significantly boost investor sentiment and BCAX stock trajectory.
Bicara Therapeutics Inc. (BCAX) reported fourth quarter and full-year 2025 financial results and provided a business update. Q4 and full-year financial results with business update moderately affect financial performance and market sentiment.
25 Mar
BofA assigns buy rating to Bicara Therapeutics (BCAX), citing standard-of-care potential for cancer drug Ficera in frontline PD-L1-high head and neck cancer. BofA buy rating on Ficera's SoC potential signals major boost to investor sentiment and BCAX trajectory.
13 Mar
Bicara Therapeutics presented data on Ficerasfusp Alfa, outlined pivotal trial timeline, and announced $172M funding raise at a conference. Clinical data updates, pivotal trial plans, and $172M raise represent major advancements in pipeline progress and financial runway.
7 Mar
Bicara Therapeutics (BCAX) valuation reassessed after new FICERA clinical data release and announcement of accelerated approval plan. New FICERA clinical data and accelerated approval plan signal major regulatory and market advancements for BCAX.
6 Mar
Bicara Therapeutics showcased promising FICERA trial data and outlined the pivotal FORTIFY study path at the TD Cowen Conference. Strong clinical data supporting pivotal trial advancement boosts regulatory and commercialization prospects significantly.
26 Feb
Bicara Therapeutics Inc. (BCAX) closed its oversubscribed public offering, with underwriters fully exercising their option to purchase additional shares. Oversubscribed offering and full underwriter option exercise provide substantial capital to fuel development and boost investor confidence.
24 Feb
Bicara Therapeutics Inc. (BCAX) priced a $150 million underwritten public offering of common stock and pre-funded warrants, expecting gross proceeds of $150 million before expenses. A $150 million capital raise significantly strengthens Bicara Therapeutics' balance sheet, funding clinical trials and extending operational runway amid biotech development needs.
Bicara Therapeutics Inc. (BCAX) announces proposed public offering of common stock, with proceeds intended for general corporate purposes including research and development, subject to market conditions and SEC review. Proposed stock offering provides critical capital for biotech R&D but introduces shareholder dilution, significantly shaping financial trajectory and market sentiment.
23 Feb
Bicara Therapeutics Inc. (BCAX) presented new FICERA trial data demonstrating potential for less frequent dosing of ficerafusp alfa with pembrolizumab in head and neck cancer, showing promising efficacy and safety. New FICERA data supporting less frequent dosing improves treatment convenience, efficacy profile, and commercial potential for BCAX's lead asset in head and neck cancer.